피망 바카라ming to increase novel drug development efficiency and expedite global clinical progress
[by Ji, Yong Jun] Kangstem Biotech announced on May 15 that it has recently signed a memorandum of understanding (MOU) with Connecteve to jointly establish a scientific and highly efficient clinical development strategy for 'OSCA,' an osteoarthritis treatment candidate, using artificial intelligence (AI) image analysis techniques. The company highlighted that this partnership is expected to increase new drug development efficiency and expedite global clinical progress.
Under the agreement, the two companies plan to pursue the following initiatives: research on 피망 바카라 image analysis-based diagnosis and treatment response prediction for osteoarthritis patients, patient classification and personalized treatment strategy development using image data, and analysis of disease progression rates in osteoarthritis patients.
Kangstem Biotech intends to leverage Connecteve's 피망 바카라-based 'Radiomics' technology, an image analysis technique that quantitatively analyzes features from medical images, such as X-rays and magnetic resonance imaging (MRI), which are typically challenging to detect through visual inspection, enabling non-invasive disease diagnosis and prognosis.
The company stated that it plans to establish a global clinical development strategy that quantitatively and statistically extracts and analyzes disease characteristics in patients with moderate knee osteoarthritis, estimates the progression rate of conditions such as treatment response and structural deterioration, and designs protocols optimized for large-scale late-stage clinical trial evaluations to increase the efficiency of novel drug development.
Connective, founded by Professor Ro Du-hyun of the Department of Orthopedic Surgery at Seoul National University Hospital, specializes in the development and provision of 피망 바카라-based image analysis solutions for orthopedic musculoskeletal disorders. The company offers a range of 피망 바카라 solutions that assist with disease diagnosis, surgical planning, and post-treatment follow-up, particularly for conditions like knee osteoarthritis. In March, Connecteve received approval from the UAE Ministry of Health for its first medical 피망 바카라 products in Korea, ‘CONNEVO KOA (Knee Osteoarthritis Diagnosis Assistant)’ and ‘CONNEVO ALI (Low-body Alignment Analysis)’, and plans to secure domestic sales approval within the year.
“The integration of 피망 바카라 technology will reinforce the late-stage and global clinical development strategies for OSCA,” s피망 바카라d Bae Yohan, Executive Managing Director of Clinical Development Division at Kangstem Biotech. “Given the diverse causes and varying disease presentations in osteoarthritis, 피망 바카라-based image analysis techniques are anticipated to play a critical role in enhancing the success rates of large-scale clinical trials, shortening development timelines, and reducing costs. We also expect this approach to improve the accuracy and efficiency of clinical trial data analysis,” he added.